This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...
Researchers report on a multinational, early phase clinical trial evaluating a new targeted therapy for patients with metastatic or unresectable non-small cell lung cancer who have a specific genetic ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC. Estelamari Rodriguez, M.D., MPH: Let’s talk a bit about ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Source: Getty Images Acute eGFR declines of greater than 15% may be a harbinger of adverse outcomes. Acute declines in estimated glomerular filtration rate (eGFR) of more than 15% over 4 months ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback